Medical/Pharmaceuticals

WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP HANGZHOU, China, Oct. 23, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading gl...

2022-10-24 08:30 2912

SK bioscience Appoints New Executives towards Global Business Growth

* Global experts continue to join SK bioscience, while its U.S. corporate entity is being established * Company plans to strategically invest in personnel, innovation & infrastructure to ensure global competitiveness SEOUL, South Korea, Oct. 21, 2022 /PRNewswire/ -- SK bioscience, a global in...

2022-10-21 20:00 3702

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

HONG KONG, Oct. 20, 2022 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso"), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced that the Center for Drug Evaluation (CDE) of China Nation...

2022-10-21 09:15 2751

132nd Canton Fair Gives Full Play to the Advantages of China's Medical and Health Industry to Provide Quality Health Care Choices

GUANGZHOU, China, Oct. 20, 2022 /PRNewswire/ -- The 132nd Canton Fair, which started onOctober 15th, 2022, gathers leading companies from China's health industr -- giving full play to its industry advantages and while providing global consumers with better health care choices. Among them, Crown ...

2022-10-20 20:49 2155

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inthe United States. This study will eva...

2022-10-20 16:20 2502

BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing

BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencing inAustralia, paving the way for the global life sciences company to provide clinical sequencing ...

2022-10-20 15:27 2180

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

SUZHOU, China and ROCKVILLE, Md., Oct. 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release results from the Phase I fir...

2022-10-20 07:16 2248

SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022

The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specificity in 27 different cancer types as a whole. In both retrospective and prospective studies, the solid performance of SeekInCare® puts it into best-in-class category of multi-cancer early detection (...

2022-10-19 20:30 1714

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

* F-18 Pivalate PET shows high uptake regardless of origin of primary tumour * F-18 Pivalate can be used to monitor cerebral metastases * Patients without previous external beam radiation show higher tumour uptake, while those previously treated show a trend towards lower uptake MELBOURNE, A...

2022-10-19 11:12 1885

STANDIGM TO ATTEND BIO-EUROPE® 2022

Standigm will present AI-driven drug discovery technology at the conference CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm , the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe

2022-10-19 01:50 2342

CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatthe National Medical Products Administration (NMPA) ofChina has a...

2022-10-18 20:50 3896

Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea

GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ -- Zhiyi Biotech announced that FDA has approved the Company's Investigational New Drug (IND) application to develop SK10 (InactivatedBacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Z...

2022-10-18 20:35 1554

Axiomtek Unleashes IP69K/IP66-Rated 10.4" Stainless Steel Fanless Touch Panel Computer for Food Processing Industry - GOT810-316

TAIPEI, Oct. 17, 2022 /PRNewswire/ -- Axiomtek – a world-renowned leader relentlessly devoted in the research, development and manufacture of series of innovative and reliable industrial computer products of high efficiency – is pleased to announce theGOT810-316, a 10.4-inch stainless steel fanle...

2022-10-18 11:41 2099

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicat...

2022-10-17 20:05 2081

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology dru...

2022-10-17 20:00 2215

PENTAX Medical launches the C2 CryoBalloon(TM) Ablation System in Canada for the treatment of Barrett's Esophagus.

MISSISSAUGA, ON, Oct. 14, 2022 /PRNewswire/ -- PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today the Canadian launch of the C2 CryoBalloon™ Ablation System for the treatment of Barrett's Esophagus. "With the launch of C2 CryoBalloon A...

2022-10-15 03:57 2345

Tianfu International Biocity: Build Global Bioindustry-city

CHENGDU, China, Oct. 14, 2022 /PRNewswire/ -- On Oct.10, Chengdu Tianfu Global International Biocity saw the signing of ten project agreements totalling nearly 9B CNY in value and covering modern biopharmaceuticals, innovative chemical drugs, sophisticated medical apparatuses and other important f...

2022-10-14 20:48 1924

Fosun Pharma's MSCI ESG Rating Upgraded to A

SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- The world's leading index company Morgan Stanley Capital International ("MSCI") recently announced its latest annual Environmental, Social and Governance ("ESG") rating results. In recognition of its outstanding performance in ESG,MSCI upgraded the ESG rati...

2022-10-14 08:26 3983

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying t...

2022-10-13 22:25 2299

First in North America: Jolly Good Hosts Clinical VR Multi Seminar in Boston, Aiming for Mass Production of UGC Medical VR

At the Boston Convention Center on Tuesday, October 25, 2022 TOKYO, Oct. 13, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good") will hold a large-scale seminar on clinical training VR produced by the UGC* medical VR platform "JOLLYGO...

2022-10-13 21:00 2157
1 ... 202203204205206207208 ... 261

Week's Top Stories